Rigrodsky & Long, P.A. Investigates Genoptix, Inc. Buyout

  • Do you own Genoptix Inc. common stock?
  • Did you purchae your shares prior to January 24, 2011?
  • Do you feel the Company's sale to Novartis is unfair?
  • Do you want to discuss your rights?

If the answer to these questions is "yes," please contact the deal lawyers at Rigrodsky & Long, P.A. ("R & L") today to schedule a FREE consultation. Just call us, or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.

Contact R & L today to be sure your best interests are being protected.

R & L is national law firm with decades of combined legal experience. R & L is investigating potential claims against the board of directors of Genoptix, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Novartis in a transaction with an approximate total equity value of $470 million.

Click here to read the full press release.

Rigrodsky & Long, P.A. Investigates Genoptix, Inc. Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Genoptix, Inc. (“Genoptix” or the “Company”) (Nasdaq: GXDX) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Novartis in a transaction with an approximate total equity value of $470 million.

Under the proposed agreement, Novartis will commence an all cash tender offer for all outstanding shares of common stock of Genoptix at $25.00 per share. Additionally, each of Genoptix’ directors and executive officers has agreed to tender their shares in the offer.

The investigation concerns whether Genoptix’ board of directors failed to adequately shop the Company and obtain the best price possible for Genoptix’ shareholders before entering into the agreement with Novartis. Indeed, according to Yahoo! Finance, at least one analyst has set a $28.00 per share price target for Genoptix stock.

If you own the common stock of Genoptix and purchased your shares before January 24, 2011, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky, Esquire or Noah R. Wortman, Case Development Director, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware, by telephone at (888) 969-4242, or by e-mail to info@rigrodskylong.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

R & L, with offices in Delaware and New York, litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Learn more about R&L:  Visit Our Website |  Our Firm  |  Our Practice Areas  |  FAQ's

Fill out the form below or call us toll-free at 888-969-4242, for a FREE no-obligation consultation.